Education
About Us
Working with TipRanks
Follow Us
Argenx (ARGX)
:ARGX
ARGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$428.76 - $678.21
Previous CloseN/A
Volume151.62K
Average Volume (3M)311.64K
Market Cap
$34.51B
Enterprise Value$5.16B
Total Cash (Recent Filing)$3.38B
Total Debt (Recent Filing)€39.05M
Price to Earnings (P/E)40.3
Beta0.51
Next Earnings
Jul 31, 2025EPS Estimate
2.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.58
Shares Outstanding61,059,563
10 Day Avg. Volume337,845
30 Day Avg. Volume311,643
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)4.68
Price to Sales (P/S)0.00
P/FCF Ratio53.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$756.58Price Target Upside34.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Argenx Se News
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe large commercial opportunity for efgartigimod is expected as it continues to expand into several additional indications.
Product Efficacy And SafetyVyvgart has become the biologic of choice due to its efficacy, favorable safety, and flexible dosing, aligning with real-world experiences of significant symptom reduction.
Regulatory ApprovalsFDA granted Vyvgart Fast Track Designation for the treatment of Sjogren's disease, indicating the agency recognized FcRn's potential and its intention to accelerate the delivery of treatment to address unmet needs.
Bears Say
Data VariabilityThe serum IgG reduction level varies with measurement methods, making comparison across different companies' experiments invalid.
Regulatory And Clinical RisksRisks include regulatory and clinical, as many indications are still in clinical trials and not approved; commercial, as argenx has launched in what is expected to become a competitive market.
Ownership Overview
―
Insiders
13.82% Mutual Funds
20.15% Other Institutional Investors
64.51% Public Companies and Individual Investors
ARGX FAQ
What was Argenx’s price range in the past 12 months?
Argenx lowest stock price was $428.76 and its highest was $678.21 in the past 12 months.
What is Argenx’s market cap?
Argenx’s market cap is $34.51B.
When is Argenx’s upcoming earnings report date?
Argenx’s upcoming earnings report date is Jul 31, 2025 which is in 34 days.
How were Argenx’s earnings last quarter?
Argenx released its earnings results on May 08, 2025. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.421 by $0.159.
Is Argenx overvalued?
According to Wall Street analysts Argenx’s price is currently Undervalued.
Does Argenx pay dividends?
Argenx does not currently pay dividends.
What is Argenx’s EPS estimate?
Argenx’s EPS estimate is 2.98.
How many shares outstanding does Argenx have?
Argenx has 61,059,563 shares outstanding.
What happened to Argenx’s price movement after its last earnings report?
Argenx reported an EPS of $2.58 in its last earnings report, beating expectations of $2.421. Following the earnings report the stock price went down -8.638%.
Which hedge fund is a major shareholder of Argenx?
Currently, no hedge funds are holding shares in ARGX
Argenx Se Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$756.58 (34.98% Upside)
$756.58 (34.98% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 39.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 15.0%
Last 30 Days ▲ 15.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.13%
12-Months-Change
Fundamentals
Return on Equity
17.33%
Trailing 12-Months
Asset Growth
36.55%
Trailing 12-Months
Company Description
Argenx
Argenx SE is a global biotechnology company dedicated to developing innovative therapies for the treatment of severe autoimmune diseases and cancer. Leveraging its proprietary antibody engineering platform, SIMPLE Antibody™, Argenx is focused on translating scientific breakthroughs into impactful medicines. The company operates primarily in the biopharmaceutical sector, with a core emphasis on developing antibody-based therapies. Its lead product, efgartigimod, is designed to treat patients with a range of autoimmune disorders, and the company continues to expand its pipeline with additional candidates targeting other critical diseases.
ARGX Company Deck
ARGX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant commercial success with record-breaking revenue growth and successful product launches. The company is in a strong financial position and advancing its pipeline with promising data presentations. However, there were challenges related to seasonality, gross-to-net impacts, and unique market dynamics in CIDP that affected growth. Overall, the sentiment is positive due to the strong growth and strategic advancements outweighing the lowlights.Read More>ARGX Stock 12 Month Forecast
Average Price Target
$756.58
▲(34.98%Upside)